CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes
Canagliflozin plus phentermine superior to placebo for weight loss at 26 weeks in obese, overweight
THURSDAY, March 23, 2017 (HealthDay News) -- For obese or overweight individuals without type 2 diabetes, coadministration of canagliflozin (CANA) and phentermine (PHEN) is associated with considerable weight loss and is well tolerated, according to a study published online March 13 in Diabetes Care.
Priscilla Hollander, M.D., Ph.D., from the Baylor University Medical Center in Dallas, and colleagues examined the efficacy and safety of coadministration of CANA and PHEN compared with placebo (PBO) and CANA or PHEN monotherapy in a randomized trial involving 335 individuals who were obese or overweight without type 2 diabetes. Participants were randomly allocated to receive PBO, CANA, PHEN, or coadministration of CANA/PHEN once daily.
The researchers found that, compared with PBO, CANA/PHEN coadministration provided superior weight loss from baseline at week 26 (least squares mean difference, −6.9 percent; P < 0.001). Compared with PBO, CANA/PHEN also provided superior achievement of weight loss ≥5 percent and reduction in systolic blood pressure. CANA/PHEN was generally well tolerated, with a consistent safety and tolerability profile relative to that of the individual components.
"CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes," the authors write. "Further studies are warranted to evaluate potential use of this combination for long-term weight management."
Several authors disclosed financial ties to pharmaceutical companies, including Janssen, which developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.